Because of their ability to elicit a potent Th1-skewed immune response, OMVs are being used not only for prophylactic vaccines against infectious diseases but also for designing therapeutic cancer vaccines, the efficacy of which depends on the elicitation of tumor-specific cytotoxic CD8+ T cells and CD4+ Th1 cells. This evidence concerns the gene CD8A and cancer.